Is pentosan polysulfate the same as Cartrophen?

Cartrophen (Cartrophen Vet) is a veterinary formulation of PPS widely used for dog osteoarthritis. While the active ingredient is similar, veterinary formulations are NOT approved for human use and should never be self-administered.

Can PPS damage your eyes?

Long-term oral PPS (Elmiron) use has been associated with a unique pigmentary maculopathy. The risk appears to increase with cumulative dose and duration (typically years of use). Regular eye examinations are recommended for anyone on long-term oral PPS.

Is PPS available in the UK?

PPS is available on private prescription in the UK for certain indications. It is not widely funded by the NHS. The injectable form for osteoarthritis is not as readily available as in Australia.

How does PPS compare to hyaluronic acid injections for joints?

PPS has disease-modifying potential (it may slow cartilage degradation), while hyaluronic acid mainly provides viscosupplementation (lubrication). PPS can be administered subcutaneously rather than intra-articularly. They may be complementary approaches.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 8 March 2026

Share:X Post LinkedIn

Healing & Recovery•Updated 2026-03-08•5 min read

What Is Pentosan Polysulfate? Benefits, Research & Safety

A semi-synthetic polysaccharide with anti-inflammatory and chondroprotective properties, approved for interstitial cystitis and researched for osteoarthritis.

Share:X Post LinkedIn

Also known as:

PPS

Elmiron

Cartrophen

Pentosan Polysulfate Sodium

NaPPS

BModerate human evidenceUK: Prescription-only (UK POM)WADA: Low sport risk

UK summary: UK prescription-only medicine (Elmiron) for interstitial cystitis. Veterinary equivalent (Cartrophen) is used for canine osteoarthritis. Elmiron carries an updated FDA / EMA warning regarding pigmentary maculopathy with long-term use.

Quick Facts

Overview

Pentosan Polysulfate Sodium (PPS) is a semi-synthetic, heparin-like polysaccharide derived from beechwood hemicellulose. While technically a carbohydrate rather than a peptide, PPS is frequently discussed alongside peptide therapies in joint health and recovery contexts and is included for comparative and educational purposes. PPS has multiple approved therapeutic uses: - **Elmiron (oral):** FDA-approved for interstitial cystitis/painful bladder syndrome - **Cartrophen Vet:** Widely used in veterinary medicine for osteoarthritis in dogs and horses - **Injectable PPS:** Used in some countries for thromboprophylaxis and osteoarthritis The compound has anti-inflammatory, fibrinolytic, anti-coagulant, and chondroprotective properties. Its mechanism includes inhibition of complement activation, stimulation of proteoglycan synthesis in cartilage, and protection of the glycosaminoglycan (GAG) layer in the bladder. PPS has gained significant attention in the UK and Australia for osteoarthritis management, where injectable formulations have shown promising results in clinical studies. However, concerns about a potential association with pigmentary maculopathy (retinal damage) with long-term oral use have prompted FDA warnings. In the UK, PPS is available on private prescription for certain indications and is increasingly discussed in sports medicine and joint health contexts.

Evidence standards summary

Pentosan Polysulfate — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

BModerate human evidenceOverall grade against our evidence grading methodology.

UK prescription-only medicine (Elmiron) for interstitial cystitis. Veterinary equivalent (Cartrophen) is used for canine osteoarthritis. Elmiron carries an updated FDA / EMA warning regarding pigmentary maculopathy with long-term use.

02Human evidence grade

BModerate human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Available on private prescription. Not widely NHS-funded. Veterinary formulations commonly used in animals.
EU: Available in some EU countries. Regulatory status varies by member state.
Notes: Elmiron (oral PPS) is FDA-approved for interstitial cystitis. Injectable PPS for OA is approved in some countries (Australia) but not universally. The FDA mandated label changes regarding eye risks in 2020. Veterinary PPS (Cartrophen) is widely used but is NOT approved for human use.

05Approved medical uses

Interstitial cystitis (Elmiron — MHRA-licensed POM under specialist urology).

06Unapproved / promotional claims

Best general joint-pain treatment.
Cures osteoarthritis.

07Common internet claims

Off-label musculoskeletal use promoted by some chronic-pain communities.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Best joint pain treatment”	C	Limited	Moderate	Off-label musculoskeletal use of PPS is not a UK-licensed indication. Maculopathy risk with long-term use warrants ophthalmology monitoring.
“Cures interstitial cystitis”	B	Yes	Low	Symptom improvement in some patients; not a cure; specialist urology supervision is standard.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Pigmentary maculopathy (FDA / EMA warning with long-term Elmiron — ophthalmology monitoring required).
Bleeding risk (anticoagulant properties).
GI side effects.

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Low sport riskWADA strict-liability framing applies.

13UK legal position

UK: Prescription-only (UK POM)

Available on private prescription. Not widely NHS-funded. Veterinary formulations commonly used in animals.

14EU legal position

Available in some EU countries. Regulatory status varies by member state.

15What this page cannot tell you

Whether off-label musculoskeletal use produces meaningful benefit.
Long-term maculopathy risk in off-label indications.

16Last reviewed

Last reviewed: 8 March 2026

Next review due: 8 March 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Off-label use lacks RCT evidence; maculopathy surveillance protocols vary.

19Safer alternatives / established care pathways

NHS urology specialist for interstitial cystitis.
NICE NG226 osteoarthritis pathway for joint pain.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Has my specialist discussed the pigmentary maculopathy risk if long-term Elmiron is proposed?

Discovery & History

PPS was first synthesised in the 1950s as part of research into heparin-like anticoagulant compounds. Its chemical structure resembles heparin and other naturally occurring glycosaminoglycans, giving it a range of biological activities. Initial therapeutic use focused on anticoagulant and fibrinolytic properties. The discovery that PPS could protect the bladder's GAG layer led to its development for interstitial cystitis, and Baker Norton Pharmaceuticals obtained FDA approval for Elmiron in 1996. In veterinary medicine, PPS (as Cartrophen) became one of the most widely used disease-modifying osteoarthritis drugs (DMOADs) for dogs, with extensive evidence supporting its chondroprotective effects. Research into human osteoarthritis applications accelerated in the 2000s and 2010s, with clinical trials in Australia showing significant benefits with subcutaneous PPS injections for knee osteoarthritis. In 2018-2019, reports emerged linking long-term oral PPS (Elmiron) use to a unique pigmentary maculopathy. This led to FDA label updates and increased ophthalmological monitoring requirements, though the risk appears dose- and duration-dependent.

Mechanism of Action

PPS exerts therapeutic effects through multiple mechanisms: **Chondroprotection** Joint-protective effects: - Stimulates proteoglycan and collagen synthesis by chondrocytes - Inhibits degradative enzymes (MMPs, aggrecanases) - Promotes synovial fluid production and quality - Reduces subchondral bone remodelling **Anti-Inflammatory Effects** Broad anti-inflammatory activity: - Inhibits complement cascade activation - Reduces inflammatory cytokine production - Inhibits neutrophil elastase - Modulates macrophage activation **GAG Layer Protection (Bladder)** Specific to interstitial cystitis: - Replenishes damaged glycosaminoglycan layer on bladder epithelium - Reduces permeability of bladder wall - Decreases irritant contact with sensory nerves - Anti-inflammatory effects reduce bladder wall inflammation **Fibrinolytic and Vascular Effects** Additional therapeutic properties: - Enhances tissue plasminogen activator release - Mild anticoagulant activity - Improves microcirculation - Reduces fibrin deposition in tissues

Researched Benefits

Based on preclinical and clinical research findings:

1
Approved for interstitial cystitis/painful bladder syndrome
2
Chondroprotective effects in osteoarthritis (strong veterinary evidence)
3
Human OA trials showing pain reduction and functional improvement
4
Anti-inflammatory effects across multiple tissues
5
Improved joint function and reduced stiffness
6
Potential disease-modifying effects in OA
7
Fibrinolytic and microcirculation benefits

Claim vs Evidence

How popular claims about Pentosan Polysulfate stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Best joint pain treatment”	C	Limited	Moderate	Off-label musculoskeletal use of PPS is not a UK-licensed indication. Maculopathy risk with long-term use warrants ophthalmology monitoring.
“Cures interstitial cystitis”	B	Yes	Low	Symptom improvement in some patients; not a cure; specialist urology supervision is standard.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Oral: 100mg three times daily (Elmiron for IC). Injectable: 2mg/kg subcutaneous (OA research protocols)
Frequency	Oral: three times daily. Injectable: typically twice weekly for 4 weeks, then weekly maintenance
Duration	IC: months to years. OA: initial 4-8 week course with periodic maintenance
Notes	PPS is a prescription medication. Oral form (Elmiron) has FDA warnings about potential retinal toxicity with long-term use. Regular eye examinations recommended. Injectable forms used in some countries for OA. Veterinary formulations must not be used in humans.

Administration Routes

Routes studied in research settings (educational only):

Oral (Elmiron capsules — approved for IC)
Subcutaneous injection (OA research and some countries)
Intramuscular injection (some protocols)

Half-Life	Stability
Approximately 4.8 hours (oral); longer for injectable due to tissue binding	Stable oral capsules; injectable solutions stored per manufacturer guidelines

Safety Profile & Known Risks

Commonly Reported Side Effects

Gastrointestinal discomfort (nausea, diarrhoea)
Headache
Hair loss (reversible, with oral use)
Mild bruising (anticoagulant effect)
Injection site reactions (injectable)

Rare Risks & Concerns

Pigmentary maculopathy with long-term oral use (FDA warning)
Bleeding complications (anticoagulant properties)
Liver function abnormalities
Thrombocytopenia

Contraindications

Active bleeding or bleeding disorders
Concurrent anticoagulant therapy (relative)
Hepatic impairment
Pregnancy and breastfeeding
Pre-existing retinal disease (requires careful monitoring)

UK & EU Regulatory Context

🇬🇧 United Kingdom

Available on private prescription. Not widely NHS-funded. Veterinary formulations commonly used in animals.

🇪🇺 European Union

Available in some EU countries. Regulatory status varies by member state.

Elmiron (oral PPS) is FDA-approved for interstitial cystitis. Injectable PPS for OA is approved in some countries (Australia) but not universally. The FDA mandated label changes regarding eye risks in 2020. Veterinary PPS (Cartrophen) is widely used but is NOT approved for human use.

Clinical Studies Summary

Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis.

Pentosan polysulfate is more efficacious than placebo in the treatment of pain, urgency, and frequency associated with interstitial cystitis. Pentosan polysulfate is not significantly different from placebo in treating nocturia associated with interstitial cystitis.

Urology. 1997View on PubMed

Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome.

IC/BPS is a heterogeneous clinical syndrome. Even though patients present with similar symptoms of bladder/pelvic pain and pressure/discomfort associated with urinary frequency and strong urge to urinate, there are subgroups or phenotypes within IC/BPS. Except for patients with Hunner lesions, initial treatment should typically be nonsurgical. Concurrent, multi-modal therapies may be offered.

J Urol. 2022View on PubMed

Systematic review of pharmacological management in Creutzfeldt-Jakob disease: no options so far?

None of the drugs evaluated proved significantly effective in increasing survival in patients with CJD. Flupirtine appears to have a beneficial effect in reducing cognitive deterioration in patients with CJD. However, additional studies are needed to establish better evidence and therapeutic options for the management of patients with CJD.

Arq Neuropsiquiatr. 2022View on PubMed

Pentosan Polysulfate Maculopathy: What Urologists Should Know in 2020.

Although the nature of the published studies renders them prone to confounders, currently available data suggest an increased risk for developing maculopathy after years of pentosan polysulfate sodium use.

Urology. 2021View on PubMed

A post-trial follow-up study of pentosan polysulfate monotherapy on preventing recurrent urinary tract infection in women.

In this study, sixteen weeks of PPS monotherapy in women with recurrent UTI significantly reduced the numbers of recurrent UTI episodes during the 2-year follow-up. The intervention drugs of oral PPS (Urosan®) was sponsored by TCM Biotech International Corporation (Taipei, Taiwan).

Sci Rep. 2022View on PubMed

Global Consensus on Interstitial Cystitis/Bladder Pain Syndrome: An Update on Therapeutic Treatments.

In this review, we present currently available treatment options for IC/BPS. These include conservative therapies, oral medications, intravesical therapies, and neuromodulation. Novel and investigational therapies are presented as well as promise for future directions.

Neurourol Urodyn. 2026View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 4

Approved product

Yes

ELMIRON

13 of 15 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

PHASE2

Status: Recruiting · 43 participants · Beijing Tongren Hospital

Conditions: Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)

No results postedNCT07523737

Persona SoluTion PPS Femur PMCF

N/A

Status: Enrolling By Invitation · 200 participants · Zimmer Biomet

Conditions: Rhematoid Arthritis, Osteo Arthritis of the Knee, Traumatic Arthritis of Knee (Diagnosis)

No results postedNCT07286513

A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.

PHASE3

Status: Recruiting · 466 participants · Paradigm Biopharmaceuticals Ltd.

Conditions: Osteoarthritis, Knee

No results postedNCT06917404

Impact of a High-resolution Program for the Prevention of Suicidal Behavior in At-risk Adults: a Quasi-experimental Ambispective Cohort Study

Status: Recruiting · 198 participants · University of Salamanca

Conditions: Prevention of Suicidal Behavior

No results postedNCT07655986

ISTDP for Patients with Treatment Resistance PPS

Status: Not Yet Recruiting · 40 participants · Daniel Maroti

Conditions: Somatic Symptom Disorder, Persistent Physical Symptoms, Functional Somatic Syndrome

No results postedNCT06682104

Comparing Effectiveness of Physician-assisted Versus Self-assisted Pap Smear Collection

Status: Recruiting · 200 participants · Morehouse School of Medicine

Conditions: Cervical Cancer Screening

No results postedNCT06229275

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

PHASE2

Status: Completed · 224 participants · Sanofi

Conditions: Dermatitis Atopic

No results postedNCT06015308

Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction

PHASE3

Status: Enrolling By Invitation · 148 participants · Erasmus Medical Center

Conditions: Cholangiocarcinoma Non-resectable, Gall Bladder Cancer, Liver Metastasis

No results postedNCT06671418

Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain

N/A

Status: Completed · 133 participants · Paradigm Biopharmaceuticals Ltd.

Conditions: Osteoarthritis, Knee

No results postedNCT04814719

The SongDanceT1 Study: Stress, Ongoing Self- Monitoring and Diabetes, Nerve Stimulation and Cognitive Empowerment.

Status: Unknown · 120 participants · Steno Diabetes Center Copenhagen

Conditions: Autonomic Dysfunction, Stress, Psychological

No results postedNCT06087679

Inhibitory Effect of a Polyphenol Supplement on Dietary Iron Absorption in Adults with Thalassemia

Status: Completed · 20 participants · Swiss Federal Institute of Technology

Conditions: Thalassemia, Iron Overload

No results postedNCT05326503

Radiation Cystitis Treated With Pentosan Polysulfate Sodium Trial

PHASE2/PHASE3

Status: Recruiting · 72 participants · National Taiwan University Hospital

Conditions: Radiation Cystitis

No results postedNCT05245591

Adverse event reports (FDA FAERS)

nausea39
off label use38
constipation32
condition aggravated29
abdominal pain27
vomiting27
drug intolerance24
somnolence24
drug ineffective23
pulmonary embolism22

FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Pentosan Polysulfate?

Source research-grade Pentosan Polysulfate from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Pentosan Polysulfate